Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Chen Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5223-2725; OpenAlex author ID A5021873644. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 12

  1. Mitocytosis-inducing nanoparticles alleviate gemcitabine resistance via dual disruption of pyrimidine synthesis and redox homeostasis in pancreatic ductal aden… Last author DOI 10.1016/j.biomaterials.2025.123630↗
  2. Size switchable nanomodulator achieving ratio-precise dual-drug codelivery for synergistic glutamine metabolism modulation in pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2026.124406↗
  3. Cascade-Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer. Last author DOI 10.1002/advs.202507118↗
  4. Transcytosis-Triggering Nanoparticles for Overcoming Stromal Barriers and Reversing Immunosuppression in Pancreatic Cancer Combinatorial Therapy. Co-author DOI 10.1021/acs.nanolett.4c06372↗
  5. Intelligent micelles for on-demand drug delivery targeting extracellular matrix of pancreatic cancer. Last author DOI 10.1016/j.jconrel.2024.07.058↗
  6. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment. Co-author DOI 10.1016/j.actbio.2023.05.047↗
  7. Penetrating Micelle for Reversing Immunosuppression and Drug Resistance in Pancreatic Cancer Treatment. Last author DOI 10.1002/smll.202107712↗
  8. Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2021.121306↗
  9. Smart hypoxia-responsive transformable and charge-reversible nanoparticles for the deep penetration and tumor microenvironment modulation of pancreatic cancer. Last author DOI 10.1016/j.biomaterials.2022.121599↗
  10. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma. First author DOI 10.1080/17425247.2022.2045943↗
  11. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy. Co-author DOI 10.1039/d0tb00017e↗
  12. Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer. Last author DOI 10.1021/acs.nanolett.9b00374↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haolin Song · 7 shared papers, 2022–2026 · strength 1.60
  2. Qinjun Chen · 7 shared papers, 2019–2026 · strength 1.35
  3. Tao Sun · 8 shared papers, 2019–2026 · strength 1.22
  4. Hongrui Fan · 5 shared papers, 2023–2026 · strength 1.14
  5. Yu Wang · 6 shared papers, 2022–2026 · strength 1.13
  6. Chufeng Li · 4 shared papers, 2022–2025 · strength 0.86
  7. Hongyi Chen · 4 shared papers, 2022–2025 · strength 0.62
  8. Shilin Zhang · 3 shared papers, 2023–2026 · strength 0.61
  9. Yifan Luo · 4 shared papers, 2022–2023 · strength 0.53
  10. Qingbing Wang · 2 shared papers, 2020–2022 · strength 0.26
  11. Chen Liang · 2 shared papers, 2019–2022 · strength 0.20
  12. Wenxi Zhou · 2 shared papers, 2019–2022 · strength 0.20
  13. Xianjun Yu · 2 shared papers, 2019–2022 · strength 0.20
  14. Xinli Chen · 2 shared papers, 2019–2022 · strength 0.20
  15. Si Shi · 2 shared papers, 2019–2022 · strength 0.20
  16. Yu Zhou · 1 shared paper, 2022 · strength 0.12
  17. Zhongmin Wang · 1 shared paper, 2020 · strength 0.11
  18. Fuyou Li · 1 shared paper, 2020 · strength 0.11
  19. Wei Huang · 1 shared paper, 2020 · strength 0.11
  20. Xiaoyi Ding · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.